-Amendments to the Claims-

Amend claims 26 and 43 - 46; cancel claims 27 - 42 and 47; and add new claims 48 - 54 as follows:

1. (Original) A compound of the formula



(I)

or a pharmaceutically acceptable salt or solvate thereof, wherein

R^1 is (i) H, (ii) C_1-C_6 alkyl optionally substituted by 1 or 2 substituents each independently selected from phenyl, naphthyl and fluorenyl, said phenyl, naphthyl and fluorenyl being optionally substituted by C_1-C_6 alkyl, C_1-C_6 alkoxy, halo or cyano, or (iii) fluorenyl;

R^2 is H or C_1-C_6 alkyl;

either, R^3 and R^4, taken together with the nitrogen atom to which they are attached, represent azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperidinyl or homopiperazinyl, each being optionally substituted on a ring nitrogen or carbon atom by C_1-C_6 alkyl or C_3-C_8 cycloalkyl and optionally substituted on a ring carbon atom not adjacent to a ring nitrogen atom by

$-NR^6R^7$ or $-OR^9$,

or, R^3 is H, C_1-C_6 alkyl, C_3-C_8 cycloalkyl or benzyl, said C_1-C_6 alkyl being optionally substituted by C_3-C_8 cycloalkyl, and R^4 is

(a) C_1-C_6 alkyl, C_3-C_8 cycloalkyl or R^{15}, said C_1-C_6 alkyl being optionally substituted by R^{15}; or

(b) $-(C_2$-C_6 alkylene$)-R^8$, or

(c) $-(C_1$-C_6 alkylene$)-R^{13}$;

R^5 is $-CH_2OH$ or $-CONR^{14}R^{14}$;

R^6 and R^7 are either each independently H or C_1-C_6 alkyl or, taken together with the nitrogen atom to which they are attached, represent azetidinyl, pyrrolidinyl or piperidinyl, said azetidinyl, pyrrolidinyl and piperidinyl being optionally substituted by C_1-C_6 alkyl;

R^8 is (i) azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, piperazin-1-yl, homopiperidin-1-yl, homopiperazin-1-yl or tetrahydroisoquinolin-1-yl, each being optionally substituted on a ring carbon atom by C_1-C_6 alkyl, C_3-C_8 cycloalkyl, phenyl, C_1-C_6 alkoxy-(C_1-C_6)-alkyl, R^9R^9N-(C_1-C_6)-alkyl, fluoro-(C_1-C_6)-alkyl, -$CONR^9R^9$, -$COOR^9$ or C_2-C_5 alkanoyl, optionally substituted on a ring carbon atom not adjacent to a ring nitrogen atom by fluoro-(C_1-C_6)-alkoxy, halo, -OR^9, cyano, -$S(O)_mR^{10}$, -NR^9R^9, -$SO_2NR^9R^9$, -NR^9COR^{10} or -$NR^9SO_2R^{10}$ and optionally benzo-fused, and said piperazin-1-yl and homopiperazin-1-yl being optionally substituted on the ring nitrogen atom not attached to the C_2-C_6 alkylene group by C_1-C_6 alkyl, phenyl, C_1-C_6 alkoxy-(C_2-C_6)-alkyl, R^9R^9N-(C_2-C_6)-alkyl, fluoro-(C_1-C_6)-alkyl, C_2-C_5 alkanoyl, -$COOR^{10}$, C_3-C_8 cycloalkyl, -SO_2R^{10}, -$SO_2NR^9R^9$ or -$CONR^9R^9$, or

(ii) -$NR^{11}R^{12}$;

R^9 is H, C_1-C_6 alkyl, C_3-C_8 cycloalkyl or phenyl;

R^{10} is C_1-C_6 alkyl, C_3-C_8 cycloalkyl or phenyl;

R^{11} is C_1-C_6 alkyl, C_3-C_8 cycloalkyl or benzyl;

R^{12} is C_1-C_6 alkyl, C_3-C_8 cycloalkyl, phenyl, benzyl, fluoro-(C_1-C_6)-alkyl, -$CONR^9R^9$, -$COOR^{10}$, -COR^{10}, -SO_2R^{10} or -$SO_2NR^9R^9$, said C_1-C_6 alkyl being optionally substituted by phenyl;

R^{13} is phenyl, pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, each being optionally substituted by C_1-C_6 alkyl, C_1-C_6 alkoxy, halo or cyano;

R^{14} is H or C_1-C_6 alkyl optionally substituted by cyclopropyl;

R^{15} is azetidin-3-yl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, homopiperidin-3-yl or homopiperidin-4-yl, each being optionally substituted by R^{13}, C_1-C_6 alkyl, C_3-C_8 cycloalkyl or benzyl;

m is 0, 1 or 2;

X is -CH_2- or -CH_2CH_2-; and

Y is CO, CS, SO_2 or C=N(CN).

2. (Original) A compound of the formula (I), as defined in claim 1, wherein

R^1 is H, C_1-C_6 alkyl or fluorenyl, said C_1-C_6 alkyl being optionally substituted by 1 or 2 substituents each independently selected from phenyl and naphthyl, said phenyl and naphthyl being optionally substituted by C_1-C_6 alkyl, C_1-C_6 alkoxy, halo or cyano;

R^2 is H or C_1-C_6 alkyl;

either, R^3 and R^4, taken together with the nitrogen atom to which they are attached, represent azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperidinyl or homopiperazinyl, each being optionally substituted on a ring nitrogen or carbon atom by C_1-C_6 alkyl or C_3-C_8 cycloalkyl and optionally substituted on a ring carbon atom not adjacent to a ring nitrogen atom by

$-NR^6R^7$,

or, R^3 is H, C_1-C_6 alkyl, C_3-C_8 cycloalkyl or benzyl and R^4 is

(a) azetidin-3-yl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, homopiperidin-3-yl or homopiperidin-4-yl, each being optionally substituted by C_1-C_6 alkyl, C_3-C_8 cycloalkyl or benzyl, or

(b) -(C_2-C_6 alkylene)-R^8, or

(c) -(C_1-C_6 alkylene)-R^{13};

R^5 is $-CH_2OH$ or $-CONR^{14}R^{14}$;

R^6 and R^7 are either each independently H or C_1-C_6 alkyl or, taken together with the nitrogen atom to which they are attached, represent azetidinyl, pyrrolidinyl or piperidinyl, said azetidinyl, pyrrolidinyl and piperidinyl being optionally substituted by C_1-C_6 alkyl;

R^8 is (i) azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, piperazin-1-yl, homopiperidin-1-yl, homopiperazin-1-yl or tetrahydroisoquinolin-1-yl, each being optionally substituted on a ring carbon atom by C_1-C_6 alkyl, C_3-C_8 cycloalkyl, phenyl, C_1-C_6 alkoxy-(C_1-C_6)-alkyl, R^9R^9N-(C_1-C_6)-alkyl, fluoro-(C_1-C_6)-alkyl, $-CONR^9R^9$, $-COOR^9$ or C_2-C_5 alkanoyl, and optionally substituted on a ring carbon atom not adjacent to a ring nitrogen atom by fluoro-(C_1-C_6)-alkoxy, halo, $-OR^9$, cyano, $-S(O)_mR^{10}$, $-NR^9R^9$, $-SO_2NR^9R^9$, $-NR^9COR^{10}$ or $-NR^9SO_2R^{10}$, and said piperazin-1-yl and homopiperazin-1-yl being optionally substituted on the ring nitrogen atom not attached to the C_2-C_6 alkylene group by C_1-C_6 alkyl, phenyl, C_1-C_6 alkoxy-(C_2-C_6)-alkyl, R^9R^9N-(C_2-C_6)-alkyl, fluoro-(C_1-C_6)-alkyl, C_2-C_5 alkanoyl, $-COOR^{10}$, C_3-C_8 cycloalkyl, $-SO_2R^{10}$, $-SO_2NR^9R^9$ or $-CONR^9R^9$, or

(ii) $-NR^{11}R^{12}$;

R^9 is H, C_1-C_6 alkyl, C_3-C_8 cycloalkyl or phenyl;

R^{10} is C_1-C_6 alkyl, C_3-C_8 cycloalkyl or phenyl;

R^{11} is H, C_1-C_6 alkyl, C_3-C_8 cycloalkyl or benzyl;

R^{12} is H, C_1-C_6 alkyl, C_3-C_8 cycloalkyl, phenyl, benzyl, fluoro-(C_1-C_6)-alkyl, $-CONR^9R^9$, $-COOR^{10}$, C_2-C_5 alkanoyl or $-SO_2NR^9R^9$;

R^{13} is phenyl, pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, each being optionally substituted by C_1-C_6 alkyl, C_1-C_6 alkoxy, halo or cyano;

R^{14} is H or C_1-C_6 alkyl optionally substituted by cyclopropyl;
m is 0, 1 or 2;
X is $-CH_2-$ or $-CH_2CH_2-$; and
Y is CO, CS, SO_2 or C=N(CN).

3. (Original) A compound as claimed in claim 1 wherein R^1 is C_1-C_6 alkyl optionally substituted by 1 or 2 substituents each independently selected from phenyl, naphthyl and fluorenyl, said phenyl, naphthyl and fluorenyl being optionally substituted by C_1-C_6 alkyl, C_1-C_6 alkoxy, halo or cyano.

4. (Original) A compound as claimed in claim 3 wherein R^1 is 2,2-diphenyleth-1-yl, 2,2-di(4-chlorophenyl)eth-1-yl, 2,2-di(3-chlorophenyl)eth-1-yl, 2,2-di(4-methylphenyl)eth-1-yl, 2,2-di(3-methylphenyl)eth-1-yl, naphth-1-ylmethyl or fluoren-9-ylmethyl.

5. (Original) A compound as claimed in claim 1 or claim 2 wherein R^2 is H or C_1-C_4 alkyl.

6. (Original) A compound as claimed in claim 5 wherein R^2 is H or methyl.

7. (Original) A compound as claimed in claim 1 or claim 2 wherein R^3 is H or C_1-C_6 alkyl.

8. (Original) A compound as claimed in claim 7 wherein R^3 is H or methyl.

9. (Original) A compound as claimed in claim 1 wherein R^4 is (a) C_1-C_4 alkyl substituted by $-R^{15}$, C_3-C_6 cycloalkyl or $-R^{15}$; or (b) $-(C_2$-C_4 alkylene)$-R^8$, or (c) $-(C_1$-C_4 alkylene)$-R^{13}$.

10. (Original) A compound as claimed in claim 9 wherein R^4 is $-CH_2R^{15}$, cyclohexyl, $-R^{15}$, $-CH_2CH_2R^8$, $-CH_2R^{13}$ or $-CH_2CH_2R^{13}$.

11. (Original) A compound as claimed in claim 1 or claim 2 wherein R^5 is $-CH_2OH$ or $-CONH(C_1$-C_6 alkyl).

12. (Original) A compound as claimed in claim 11 wherein R^5 is -CH_2OH or -$CONHCH_2CH_3$.

13. (Original) A compound as claimed in claim 1 wherein R^8 is (i) piperidin-1-yl, optionally substituted on a ring carbon atom by C_1-C_6 alkyl, C_3-C_8 cycloalkyl, phenyl, C_1-C_6 alkoxy-(C_1-C_6)-alkyl, R^9R^9N-(C_1-C_6)-alkyl, fluoro-(C_1-C_6)-alkyl, -$CONR^9R^9$, -$COOR^9$ or C_2-C_5 alkanoyl, optionally substituted on a ring carbon atom not adjacent to a ring nitrogen atom by fluoro-(C_1-C_6)-alkoxy, halo, -OR^9, cyano, -$S(O)_mR^{10}$, -NR^9R^9, -$SO_2NR^9R^9$, -NR^9COR^{10} or -$NR^9SO_2R^{10}$ and optionally benzo-fused, or (ii) -$NR^{11}R^{12}$.

14. (Original) A compound as claimed in claim 13 wherein R^8 is piperidin-1-yl, 4-(2-propyl)piperidin-1-yl, 2,2,6,6-tetramethylpiperidin-1-yl, 1,2,3,4-tetrahydroisoquinolin-2-yl or -$NR^{11}R^{12}$.

15. (Original) A compound as claimed in claim 1 or claim 2 wherein R^{11} is C_1-C_6 alkyl or C_3-C_8 cycloalkyl.

16. (Original) A compound as claimed in claim 15 wherein R^{11} is -$CH(CH_3)_2$, -$CH_2CH_2CH_2CH_3$, -$CH_2CH(CH_3)_2$, -$C(CH_3)_3$, -$CH(CH_2CH_3)_2$, cyclohexyl or cyclopentyl.

17. (Original) A compound as claimed in claim 1 wherein R^{12} is C_1-C_6 alkyl, C_3-C_8 cycloalkyl, -COR^{10} or -SO_2R^{10} said C_1-C_6 alkyl being optionally substituted by phenyl.

18. (Original) A compound as claimed in claim 17 wherein R^{12} is -$CH(CH_3)_2$, -$CH_2CH_2CH_2CH_3$, -$CH_2CH(CH_3)_2$, -$C(CH_3)_3$, -$CH(CH_2CH_3)_2$, -$C(CH_3)_2Ph$, -SO_2Ph, -COPh, cyclohexyl or cyclopentyl.

19. (Original) A compound as claimed in claim 1 or claim 2 wherein R^{13} is phenyl or pyridin-2-yl, each being optionally substituted by C_1-C_6 alkyl, C_1-C_6 alkoxy, halo or cyano.

20. (Original) A compound as claimed in claim 18 wherein R^{13} is phenyl or pyridin-2-yl.

21. (Original) A compound as claimed in claim 1 wherein R^{15} is pyrrolidin-3-yl or piperidin-4-yl, each being optionally substituted by R^{13}, C_1-C_6 alkyl, C_3-C_8 cycloalkyl or benzyl.

22. (Original) A compound as claimed in claim 21 wherein R^{15} is 1-benzyl-piperidin-4-yl, (1-benzyl-piperidin-4-yl)methyl, 1-(2-pyridinyl)piperidin-4-yl, or 1-benzyl-pyrrolidin-3-yl.

23. (Original) A compound as claimed in claim 1 or claim 2 wherein X is $-CH_2-$.

24. (Original) A compound as claimed in claim 1 or claim 2 wherein Y is CO or C=N(CN).

25. (Original) A compound as claimed in claim 1 which is selected from the group consisting of:
N-({9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl}methyl)-*N'*-[2-(diisopropylamino)ethyl] urea;
N-({9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl}methyl)-*N'*-[2-(1-piperidinyl)ethyl]urea;
(2*S*,3*S*,4*R*,5*R*)-5-{2-{[({[2-(diisopropylamino)ethyl]amino}carbonyl)amino] methyl}-6-[(2,2-diphenylethyl)amino]-9*H*-purin-9-yl}-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;
(2*S*,3*S*,4*R*,5*R*)-5-(6-[(2,2-diphenylethyl)amino]-2-{[({[2-(1-piperidinyl)ethyl] amino}carbonyl)amino]methyl}-9*H*-purin-9-yl)-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;
(2*S*,3*S*,4*R*,5*R*)-5-{2-{[((*E*)-(cyanoimino){[2-(1-piperidinyl)ethyl]amino} methyl)amino]methyl}-6-[(2,2-diphenylethyl)amino]-9*H*-purin-9-yl}-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;
(2*S*,3*S*,4*R*,5*R*)-5-{2-({[(benzylamino)carbonyl]amino}methyl)-6-[(2,2-diphenylethyl)amino]-9*H*-purin-9-yl}-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

(2*S*,3*S*,4*R*,5*R*)-5-{2-({[(cyclohexylamino)carbonyl]amino}methyl)-6-[(2,2-diphenylethyl)amino]-9*H*-purin-9-yl}-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

(2*S*,3*S*,4*R*,5*R*)-5-{2-({[({2-[benzoyl(isopropyl)amino]ethyl}amino)carbonyl] amino}methyl)-6-[(2,2-diphenylethyl)amino]-9*H*-purin-9-yl}-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

(2*S*,3*S*,4*R*,5*R*)-5-[6-[(2,2-diphenylethyl)amino]-2-({[({2-[isopropyl(phenylsulfonyl)amino]ethyl}amino)carbonyl]amino}methyl)-9*H*-purin-9-yl]-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

N'-({9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl}methyl)-*N*-methyl-*N*-[2-(2-pyridinyl) ethyl]urea;

(2*S*,3*S*,4*R*,5*R*)-5-{2-[({[(1-benzyl-4-piperidinyl)amino]carbonyl}amino)methyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-9-yl}-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

(2*S*,3*S*,4*R*,5*R*)-5-[6-[(2,2-diphenylethyl)amino]-2-({[({2-[(1-ethylpropyl)(isobutyl)amino]ethyl}amino)carbonyl]amino}methyl)-9*H*-purin-9-yl]-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

N-({9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl}methyl)-*N'*-{2-[(1-ethylpropyl)(isobutyl)amino]ethyl}urea;

N-[2-(3,4-dihydro-2(1*H*)-isoquinolinyl)ethyl]-*N'*-({9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl}methyl)urea;

(2*S*,3*S*,4*R*,5*R*)-5-{2-{[({[2-(3,4-dihydro-2(1*H*)-isoquinolinyl)ethyl]amino} carbonyl)amino]methyl}-6-[(2,2-diphenylethyl)amino]-9*H*-purin-9-yl}-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

(2*S*,3*S*,4*R*,5*R*)-5-{2-{[({[2-(dibutylamino)ethyl]amino}carbonyl)amino]methyl}-6-[(2,2-diphenylethyl)amino]-9*H*-purin-9-yl}-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

(2*S*,3*S*,4*R*,5*R*)-5-{2-({[({2-[cyclopentyl(isopropyl)amino]ethyl}amino)carbonyl] amino}methyl)-6-[(2,2-diphenylethyl)amino]-9*H*-purin-9-yl}-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

N-{2-[cyclopentyl(isopropyl)amino]ethyl}-*N'*-({9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl}methyl)urea;

(2*S*,3*S*,4*R*,5*R*)-5-(6-[(2,2-diphenylethyl)amino]-2-{[({[1-(2-pyridinyl)-4-piperidinyl]amino}carbonyl)amino]methyl}-9*H*-purin-9-yl)-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

(2*S*,3*S*,4*R*,5*R*)-5-(6-[(2,2-diphenylethyl)amino]-2-{[methyl({[2-(1-piperidinyl)ethyl]amino}carbonyl)amino]methyl}-9*H*-purin-9-yl)-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

(2*S*,3*S*,4*R*,5*R*)-5-{2-({[({2-[*tert*-butyl(cyclohexyl)amino]ethyl}amino)carbonyl]amino}methyl)-6-[(2,2-diphenylethyl)amino]-9*H*-purin-9-yl}-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

N-{2-[*tert*-butyl(cyclohexyl)amino]ethyl}-*N'*-({9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl}methyl)urea;

N-({9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl}methyl)-*N'*-[1-(2-pyridinyl)-4-piperidinyl]urea;

N-[(1-benzyl-4-piperidinyl)methyl]-*N'*-({9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl}methyl)urea;

N-[(1-benzyl-4-piperidinyl)methyl]-*N'*-({9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl}methyl)urea;

(2*S*,3*S*,4*R*,5*R*)-5-[6-[(2,2-diphenylethyl)amino]-2-({[({2-[isopropyl(1-methyl-1-phenylethyl)amino]ethyl}amino)carbonyl]amino}methyl)-9*H*-purin-9-yl]-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

N-({9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl}methyl)-*N'*-{2-[isopropyl(1-methyl-1-phenylethyl)amino]ethyl}urea;

N-[2-(dicyclopentylamino)ethyl]-*N'*-({9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl}methyl)urea;

N-({9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(9*H*-fluoren-9-ylmethyl)amino]-9*H*-purin-2-yl}methyl)-*N'*-[2-(diisopropylamino) ethyl]urea;

N-({9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl}methyl)-*N'*-[2-(2,2,6,6-tetramethyl-1-piperidinyl)ethyl]urea;

(2*S*,3*S*,4*R*,5*R*)-5-(6-[(2,2-diphenylethyl)amino]-2-{[({[2-(4-isopropyl-1-piperidinyl)ethyl]amino}carbonyl)amino]methyl}-9*H*-purin-9-yl)-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

(2*S*,3*S*,4*R*,5*R*)-5-(6-[(2,2-diphenylethyl)amino]-2-{[({[2-(2,2,6,6-tetramethyl-1-piperidinyl)ethyl]amino}carbonyl)amino]methyl}-9*H*-purin-9-yl)-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

N-[(3*R*)-1-benzylpyrrolidinyl]-*N'*-({9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl}methyl)urea;

(2*S*,3*S*,4*R*,5*R*)-5-{2-{[({[(3*R*)-1-benzylpyrrolidinyl]amino}carbonyl)amino]methyl}-6-[(2,2-diphenylethyl)amino]-9*H*-purin-9-yl}-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

(2*S*,3*S*,4*R*,5*R*)-5-(6-{[2,2-bis(4-chlorophenyl)ethyl]amino}-2-{[({[2-(diisopropylamino)ethyl]amino}carbonyl)amino]methyl}-9*H*-purin-9-yl)-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

N-({6-{[2,2-bis(4-chlorophenyl)ethyl]amino}-9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-9*H*-purin-2-yl}methyl)-*N'*-[2-(diisopropylamino)ethyl]urea;

N-({6-{[2,2-bis(3-methylphenyl)ethyl]amino}-9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-9*H*-purin-2-yl}methyl)-*N'*-[2-(diisopropylamino)ethyl]urea;

N-({6-{[2,2-bis(3-chlorophenyl)ethyl]amino}-9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-9*H*-purin-2-yl}methyl)-*N'*-[2-(diisopropylamino)ethyl]urea;

N-({6-{[2,2-bis(3-methylphenyl)ethyl]amino}-9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-9*H*-purin-2-yl}methyl)-*N'*-[2-(diisopropylamino)ethyl]urea; and

(2*S*,3*S*,4*R*,5*R*)-5-{2-{[({[2-(Diisopropylamino)ethyl]amino}carbonyl)amino]methyl}-6-[(1-naphthylmethyl)amino]-9*H*-purin-9-yl}-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

and the pharmaceutically acceptable salts and solvates thereof.

26. (Currently amended) A pharmaceutical composition comprising ~~including~~ a compound of claim 1 ~~the formula (I) or a pharmaceutically acceptable salt or solvate thereof, as defined in any one of the preceding claims~~, together with a pharmaceutically acceptable excipient, diluent or carrier.

27. - 42. (Canceled)

43. (Currently amended) A process for <u>preparing</u> ~~the preparation of~~ a compound of ~~the formula (I), as defined in~~ claim 1, or a pharmaceutically acceptable salt or solvate thereof, <u>comprising</u> ~~which includes~~

(a) <u>deprotecting</u> ~~deprotection of~~ a compound of the formula



(III)

wherein R^1, R^2, R^3, R^4, X and Y are as defined in claim 1 and either P^1, P^2 and P^3, when taken separately, are protecting groups or, P^1 and P^2, when taken together are a protecting group and P^3 is a protecting group, the protecting groups being removed together or sequentially; or

(b) <u>deprotecting</u> ~~deprotection of~~ a compound of the formula



(IIIC)

wherein R^1, R^2, R^3, R^4, X and Y are as defined in claim 1 and either P^1 and P^2, when taken separately, are protecting groups or, P^1 and P^2, when taken together are a protecting group, the protecting groups P^1 and P^2, when taken separately, being removed either together or sequentially; or

(c) <u>deprotecting</u> ~~deprotection of~~ a compound of the formula



(IIID)

wherein P^3 is a protecting group and R^1, R^2, R^3, R^4, X and Y are as defined in claim 1; or

(d) deprotecting ~~deprotection of~~ a compound of the formula



(II)

wherein R^1, R^2, R^3, R^4, R^{14}, X and Y are as defined in claim 1 and either P^1 and P^2, when taken separately, are protecting groups or, P^1 and P^2, when taken together are a protecting group, the protecting groups P^1 and P^2, when taken separately, being removed either together or sequentially;

any one of said processes (a) to (d) being optionally followed by the conversion of the compound of the formula (I) to a pharmaceutically acceptable salt thereof.

44. (Currently amended) A process for preparing ~~the preparation of~~ a compound of ~~the formula (I), as defined in~~ claim 1, or a pharmaceutically acceptable salt or solvate thereof, comprising reacting ~~which includes the reaction of~~ a compound of the formula



(XXXVIII)

wherein R^1, R^2, R^5 and X are as defined in claim 1 with

(a) a compound of the formula



(X)

wherein R^3 and R^4 are as defined in claim 1 and L^1 is a suitable leaving group~~, preferably imidazol-1-yl~~; or

(b) a compound of the formula

$$R^3R^4NSO_2L^9 \text{ (XVII)}$$

wherein R^3 and R^4 are as defined in claim 1 and L^9 is a suitable leaving group~~, preferably chloro~~; or

(c) a compound of the formula

wherein R^3 and R^4 are as defined in claim 1 and L^8 is a suitable leaving group~~, preferably methylthio or imidazol-1-yl~~; or



(XVI)

(d) a compound of the formula



(XXI)

wherein R^3 and R^4 are as defined in claim 1 and L^{13} is a suitable leaving group~~, preferably methylthio~~;

said process being optionally followed by the conversion of the compound of the formula (I) to a pharmaceutically acceptable salt thereof.

45. (Currently amended) A process for preparing ~~the preparation of~~ a compound of ~~the formula (I), as defined in~~ claim 1, or a pharmaceutically acceptable salt or solvate thereof, comprising ~~which includes~~

(a) reacting ~~the reaction of~~ a compound of the formula



(XXXIX)

wherein R^1, R^2, R^5 and X are as defined in claim 1 and L^{20} is a suitable leaving group~~, preferably imidazol-1-yl,~~ with a compound of the formula

R^3R^4NH (XI)

wherein R^3 and R^4 are as defined in claim 1; or

(b) reacting ~~the reaction of~~ a compound of the formula



(XXXX)

wherein R^1, R^2, R^5 and X are as defined in claim 1 and L^{21} is a suitable leaving group~~, preferably methylthio or imidazol-1-yl,~~ with a compound of the formula

R^3R^4NH (XI)

wherein R^3 and R^4 are as defined in claim 1; or

(c) reacting ~~the reaction of~~ a compound of the formula



(XXXXI)

wherein R^1, R^2, R^5 and X are as defined in claim 1 and L^{22} is a suitable leaving group~~, preferably methylthio,~~ with a compound of the formula

R^3R^4NH (XI)

wherein R^3 and R^4 are as defined in claim 1;

any one of said processes (a) to (c) being optionally followed by the conversion of the compound of the formula (I) to a pharmaceutically acceptable salt thereof.

46. (Currently amended) A process for preparing ~~the preparation of~~ a compound of ~~the formula (I), as defined in~~ claim 1, or a pharmaceutically acceptable salt or solvate thereof, comprising acylating ~~which includes the acylation~~ or sulphonylating ~~suphonylation of~~ a compound of the formula



(XXXXXII)

wherein R^1, R^2, R^3, R^5, R^{11}, X and Y are as defined in claim 1;

said process being optionally followed by the conversion of the compound of the formula (I) to a pharmaceutically acceptable salt thereof.

47. (Canceled)

48. (New) A process of claim 45 wherein, in step (a), L^{20} is imidazol-1-yl.

49. (New) A process of claim 45 wherein, in step (b), L^{21} is methylthio or imidazol-1-yl.

50. (New) A process of claim 45 wherein, in step (c), L^{22} is methylthio.

51. (New) A process of claim 44 wherein, in step (a), L^{1} is imidazol-1-yl.

52. (New) A process of claim 44 wherein, in step (b), L^{9} is chloro.

A2 cont'd

53. (New) A process of claim 44 wherein, in step (c), L^{8} is methylthio or imidazol-1-yl.

54. (New) A process of claim 44 wherein, in step (d), L^{13} is methylthio.